Subscribe
shutterstock_728418352_casimiropt
casimiropt / Shutterstock.com
29 October 2019AmericasSarah Morgan

Allergan pays $750m to resolve antitrust litigation

Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda (memantine hydrochloride).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug
20 August 2019   Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
Americas
Generic drugmaker to pay $3m antitrust fine
5 December 2019   New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
Americas
Allergan agrees to pay $300m to end birth control litigation
8 January 2020   Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug
20 August 2019   Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
Americas
Generic drugmaker to pay $3m antitrust fine
5 December 2019   New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
Americas
Allergan agrees to pay $300m to end birth control litigation
8 January 2020   Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

More on this story

Americas
Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug
20 August 2019   Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
Americas
Generic drugmaker to pay $3m antitrust fine
5 December 2019   New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
Americas
Allergan agrees to pay $300m to end birth control litigation
8 January 2020   Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent